
    
      Subjects randomized to the ELAD® group will receive treatment with ELAD® for a maximum of
      five (5) 24 hour periods as well as standard of care treatment.

      Subjects randomized to the Control group will receive standard of care treatment throughout
      the study.

      The ITT population includes all randomized subjects assigned to the group to which they were
      randomized, irrespective of actual treatment administered. Participant, Baseline
      Characteristics, and Outcome Measures used the ITT population. The safety population is
      defined as all subjects who are randomized based on actual treatment received. All serious
      adverse events and all non-serious adverse events analyses used the safety population.
    
  